AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• AnaptysBio has a “Moderate Buy” consensus rating from 14 analysts: 10 buys, three holds and one sell. The average 12-month price target is $80, implying potential upside from the stock’s $56.28 opening price.
• Recent analyst views remain mixed but generally positive: HC Wainwright reiterated a $95 buy target, UBS raised its target to $76, while Zacks downgraded the stock to hold and Weiss Ratings maintained a sell rating.
• ANAB has a $1.67 billion market capitalization and trades near $56, compared with a 52-week range of $11.40 to $72.36; its 50-day and 200-day moving averages are approximately $58.55 and $59.06, respectively.

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have been given an average recommendation of "Moderate Buy" by the fourteen research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $80.00.

A number of brokerages recently commented on ANAB. HC Wainwright reiterated a "buy" rating and issued a $95.00 price objective on shares of AnaptysBio in a research report on Monday, August 24th. Zacks Research downgraded shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of AnaptysBio in a research note on Friday, August 7th. UBS Group lifted their price target on shares of AnaptysBio from $60.00 to $76.00 and gave the stock a "buy" rating in a research report on Wednesday, May 13th. Finally, Leerink Partners set a $90.00 price target on shares of AnaptysBio in a research note on Friday, May 15th.

Institutional Trading of AnaptysBio

A number of institutional investors have recently bought and sold shares of the business. Persistent Asset Partners Ltd acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $39,000. Smartleaf Asset Management LLC boosted its position in shares of AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 821 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 473 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. increased its holdings in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 2,326 shares during the last quarter.

AnaptysBio Price Performance

ANAB opened at $56.28 on Friday. The stock has a market capitalization of $1.67 billion, a P/E ratio of -52.11 and a beta of 0.72. The company's 50 day simple moving average is $58.55 and its 200-day simple moving average is $59.06. AnaptysBio has a one year low of $11.40 and a one year high of $72.36.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source